What drove the volume surge in T14.SI stock today?

The volume surge followed a reported annual dividend notice and strong price momentum. Trade volume reached **210,100**, above the 50-day average. Market participants reacted to yield signals and the stock's low PE, boosting short-term demand.

Is T14.SI stock undervalued compared with peers?

On PE basis, T14.SI at **5.13** is well below the Healthcare sector average PE of **22.17**, suggesting relative undervaluation. Investors should still check earnings quality and dividend sustainability before concluding valuation.

What is Meyka AI's forecast for T14.SI stock?

Meyka AI's forecast model projects a one-year price of **S$3.97**, implying **11.45%** upside versus the current **S$3.56**. Forecasts are model-based projections and not guarantees.

What technical levels matter for trading T14.SI stock?

Key technical levels are support at the 50-day MA **S$3.28** and 200-day MA **S$2.85**, with immediate resistance near **S$3.52–S$3.57**. RSI at **61.31** indicates neutral to mildly bullish momentum.

SG Stocks

S$3.56 (up 6.59%): T14.SI Tianjin Pharma (SES) 16 Feb 2026: volume rise, yield

ByDanny Kontos February 16, 2026February 16, 2026

The T14.SI stock closed at S$3.56 on 16 Feb 2026 after a 6.59% gain on heavy trading volume of 210,100 shares. This move pushed the share price above its 50-day average of S$3.28 and kept it well above the 200-day average of S$2.85. Investors reacted to a recently published annual dividend notice and solid underlying metrics, turning T14.SI into a high-volume mover on the Singapore Exchange (SES). We break down the drivers, valuation, analyst-grade and short-term outlook.